Test-retest reliability of 12-month and lifetime cannabis use was substantial (kappa=0.78, 0.77) in a general population sample (43). Test-retest reliabilities of DSM-5 cannabis use disorders (kappa=0.41, 0.41) and their dimensional criteria scales (intraclass correlation coefficients [ICC]=0.70, 0.71) were fair to substantial in a general population sample (N=1006) (44). Procedural validity was assessed through blind clinician re-appraisal using the semi-structured, clinician-administered Psychiatric Research Interview for Substance and Mental Disorders, DSM-5 version (PRISM-5) (45) in a separate general population sample (N=712). AUDADIS-5/PRISM-5 concordance was moderate for cannabis use disorder (kappa=0.60, 0.51) and substantial for its dimensional criteria scale (ICC=0.79, 0.78) (46).
